1. Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry)
- Author
-
Ikuo Sekine, Hiroyuki Naito, Hiroko Bando, Rumi Sasamura, Noriko Iida, Keiko Inoue, Yoko Nakazawa, Kazuko Tajiri, Shigeru Chiba, Momoko Murata, Kenji Nagashio, Nobutaka Tasaka, Masaki Ieda, Siqi Li, and Tomoko Ishizu
- Subjects
medicine.medical_specialty ,cardio-oncology ,Anthracycline ,Registry study ,Cardiomyopathy ,cardiotoxicity ,lcsh:Medicine ,030204 cardiovascular system & hematology ,anthracycline ,Article ,onco-cardiology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,echocardiography ,Cardiotoxicity ,Ejection fraction ,Troponin T ,business.industry ,lcsh:R ,General Medicine ,medicine.disease ,Brain natriuretic peptide ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,biomarker ,business ,cardiomyopathy - Abstract
As the number of cancer survivors increases, cardiac management in anthracycline-treated patients has become more important. We planned to conduct a prospective multicenter registry study for comprehensive echocardiographic and biomarker data collection and an evaluation of the current practice in terms of diagnosis and management of anthracycline-induced cardiotoxicity (AIC registry). To examine the feasibility of this registry study, we analyzed the 1-year follow-up data of 97 patients registered during the first year of this registry. The AIC registry was launched in July 2016. Data on echocardiographic parameters (e.g., two-and three-dimensional [(2- and 3-D) left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS)) and biomarkers (e.g., troponin T and brain natriuretic peptide) were collected before anthracycline treatment, every 3 months during the first year after starting anthracycline, and every 6 months during the second year. Eighty-three patients (86%) completed a 1-year follow-up. The measurable rates of 2D LVEF, 3D LVEF, and GLS on each visit were nearly optimal (100%, 86–93%, and 84–94%, respectively). During the 1-year follow-up, 5 patients (6.0%) developed cardiotoxicity (a reduction in LVEF ≥ 10 percentage points from baseline and <, 55%). The AIC registry study is feasible and will be the first study to collect sizable echocardiographic and biomarker data on cardiotoxicity in Japanese patients treated with anthracycline in a real-world setting.
- Published
- 2021